Table 1.
Study design
| Nominal dose (BID SC injections) | Nominal dose concentration | Dose volume | Number of animals (males) | ||||
|---|---|---|---|---|---|---|---|
| Group number/treatment | (µg/kg/dose) | (µg/kg/day) | (µg/ml) | (ml/kg/dose) | Main | Recovery | PK |
| 1/Vehicle | 0 | 0 | 0 | 0.5 | 15 | 8 | 3 |
| 2/Exenatide | 3 | 6 | 10 | 0.3 | 15 | 8 | 9 |
| 3/Exenatide | 20 | 40 | 40 | 0.5 | 15 | 8 | 9 |
| 4/Exenatide | 125 | 250 | 250 | 0.5 | 15 | 8 | 9 |
Recovery animals were a subset of each treatment group. PK animals were used for pharmacokinetic evaluation only and were euthanized following their last blood collection. BID, twice daily; SC, subcutaneous; PK, pharmacokinetics.